Catalog No.
Product Name
Application
Product Information
Citations
- Duocarmycin is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity. Duocarmycin is a DNA minor groove binding alkylating agent and explored as drug?Cantibody conjugates (ADCs) .
- MC-Val-Cit-PAB-tubulysin5a is a drug-linker conjugate for ADC with potent antitumor activity by using tubulysin5a (a tubulin inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
- MC-Val-Cit-PAB-rifabutin is a drug-linker conjugate for ADC with potent antitumor activity by using rifabutin (an DNA-dependent RNA polymerase inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
- MC-Val-Cit-PAB-Indibulin is a drug-linker conjugate for ADC with potent antitumor activity by using Indibulin (an orally applicable inhibitor of tubulin assembly), linked via the ADC linker MC-Val-Cit-PAB.
-
protein synthesis inhibitor
MC-Val-Cit-PAB-clindamycin is a drug-linker conjugate for ADC with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB. - MC-Val-Cit-PAB-Retapamulin is a drug-linker conjugate for ADC with potent antitumor activity by using Retapamulin (a ribosome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
- MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB.
- MC-Val-Cit-PAB-duocarmycin is a drug-linker conjugate for ADC with potent antitumor activity by using duocarmycin (a DNA minor groove binding alkylating agent), linked via the ADC linker MC-Val-Cit-PAB.
- MC-Val-Cit-PAB-carfilzomib is a drug-linker conjugate for ADC with potent antitumor activity by using carfilzomib (an irreversible proteasome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
-
Drug-Linker Conjugate for ADC
Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It features a linker alongside the potent cytotoxic agent MMAE, enabling targeted delivery to cells expressing the c-Kit receptor. This compound can facilitate the synthesis of NN3201 by conjugating with NN2101 (anti c-Kit), which promotes rapid internalization and effectively disrupts SCF-driven signaling pathways. Consequently, NN3201 demonstrates significant anti-tumor activity in various cancer models, including small cell lung cancer (SCLC) and gastrointestinal stromal tumors (GIST). -
Antibody-Drug Conjugate
Loncastuximab tesirine is an antibody-drug conjugate (ADC) targeting the cluster of differentiation 19 (CD19) antigen. This compound comprises the Loncastuximab antibody linked to Tesirine, a potent cytotoxic agent. Upon binding to CD19, Loncastuximab tesirine is internalized, leading to apoptosis in malignant B-cells. This reagent is primarily utilized in research focused on diffuse large B-cell lymphoma and related hematological malignancies. -
ADC Cytotoxin
γ-Amanitin is a potent ADC cytotoxin derived from the Amanita mushroom, specifically targeting RNA polymerase II to inhibit mRNA synthesis. This compound exhibits high toxicity across various cell types, making it a valuable tool in cancer research and therapeutic applications. γ-Amanitin competes effectively with monoclonal antibodies, displaying an IC50 value of 163.1 ng/mL. Its ability to disrupt transcriptional processes positions it as a key reagent in studies focused on gene expression and cellular response mechanisms. -
Drug-linker Conjugates for ADC
MC-VC-PAB-Cyclohexanediamine-Thailanstatin A functions as a drug-linker conjugate specifically designed for antibody-drug conjugate (ADC) applications. This compound combines the potent cytotoxic properties of Thailanstatin A with a cleavable linker (MC-vc-PAB), facilitating targeted delivery and release of the drug within cancer cells. It is suitable for ADC synthesis and can be utilized in research focused on targeted cancer therapies and improved therapeutic index. -
ADC Cytotoxin
Mytoxin B is an ADC cytotoxin that functions as a satratoxin-type trichothecene macrolide. It is known for inducing cell apoptosis primarily through the PI3K/Akt signaling pathway. This compound is utilized in research applications focused on targeted cancer therapies and the study of apoptosis mechanisms in various cell types. -
Antibody-Drug Conjugate
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). This reagent exhibits potent antitumor activity and is valuable for research applications involving glioma, head and neck squamous cell carcinoma, non-small cell lung cancer, epidermoid carcinoma of the skin, and squamous cell carcinoma of the tongue. Its mechanism of action combines selective targeting of EGFR with cytotoxic delivery, making it a significant tool in cancer research and therapeutic studies. -
Antibody-Drug Conjugates
Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate that targets HER2, featuring a potent payload linked to a STING agonist. This innovative design promotes immune activation, enhancing anticancer efficacy. Its applications are particularly relevant in the development of targeted therapies for HER2-positive cancers, making it a valuable tool for cancer research. -
Antibody-drug Conjugate
Trastuzumab emtansine is an antibody-drug conjugate (ADC) that combines the HER2-targeting capabilities of trastuzumab with the cytotoxic effects of the microtubule-inhibitory agent DM1. This compound demonstrates potent antitumor activity and is particularly relevant in the study of advanced breast cancer. Its dual mechanism allows for targeted delivery of cytotoxic agents, making it a valuable tool in oncological research and therapeutic development. -
Antibody-Drug Conjugate
Disitamab vedotin is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). This reagent consists of a monoclonal antibody linked through a cleavable connector to the cytotoxic drug Monomethyl auristatin E (MMAE). Disitamab vedotin is designed to enhance antitumor immunity and is applicable in cancer research, particularly in studies focused on HER2-positive malignancies. -
Drug-Linker Conjugates for ADC
Mal-N(Me)-C6-N(Me)-PNU-159682 is a drug-linker conjugate specifically designed for antibody-drug conjugates (ADCs). This compound utilizes the Mal-N(Me)-C6-N(Me) linker to selectively deliver the cytotoxic agent PNU-159682 to CD46-expressing cells. Upon entering these cells, the linker is cleaved by cathepsin B, resulting in the release of PNU-159682, which induces DNA damage and apoptosis. Notably, Mal-N(Me)-C6-N(Me)-PNU-159682 demonstrates significant tumor regression in patient-derived xenograft models of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). -
Antibody-drug Conjugate
HE-S2 is an antibody-drug conjugate that targets the PD-1/PD-L1 interaction, thereby enhancing antitumor immune responses. By activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway, HE-S2 exhibits significant antitumor activity. This reagent is suitable for research applications involving cancer immunotherapy and the modulation of immune responses in tumor microenvironments. - Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
-
ADCs cytotoxin
PNU-159682, a highly potent metabolite of the anthracycline nemorubicin (DNA topoisomerase II inhibitor) with outstanding cytotoxicity, is a potent ADCs cytotoxin. - Boc-Gly-Gly-Phe-Gly-OH is a protease cleavable linker used for the antibody-drug conjugate (ADC).
- Boc-Dap-NE is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
-
nonclaevable ADC linker
Succinic anhydride is a cyclic anhydride and a nonclaevable ADC linker extracted from patent WO2009064913A1. Succinic anhydride can react with compound 4 of the patent to link the prodrug to an amine or hydroxy 1 group of a targeting polypeptide. -
nonclaevable ADC linker
Mal-amido-PEG8-C2-acid (example 142) is a nonclaevable ADC linker, extracted from patent US2018339985. - sulfo-SPDB-DM4 is a drug-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.
- MC-Val-Cit-PAB is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate. FDA approved drugs such as brentuximab vedotin use this linker.
-
short-chain crosslinker
SPDP (SPDP Crosslinker) is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls. It is a glutathione cleavable ADC linker used for the antibody-drug conjugates (ADCs). - 10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel (a microtubule stabilizing agent; enhances tubulin polymerization) derivative with improved pharmacological features.
- Vipivotide tetraxetan Linker (PSMA-617 Linker) is a nonclaevable peptide linker for synthesis of Vipivotide tetraxetan (PSMA-617).
-
antibody drug conjugates (ADCs) toxin
Duocarmycin MA is an antibody drug conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin MA can be used against multi-drug resistant cell lines. -
drug-linker conjugate for ADC
mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). mDPR-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. -
drug-linker conjugate for ADC
Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for ADC. -
drug-linker conjugate for ADC
Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. -
microtubulin inhibitor
Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. -
drug-linker conjugate for ADC
Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide Val-Cit-PAB. - Tubulysin A(TubA) is a myxobacterial product that can function as an antiangiogenic agent in many in vitro assays; anti-microtubule, anti-mitotic, an apoptosis inducer, anticancer, anti-angiogenic, and antiproliferative.
-
tubulin inhibitor
altobulin (HTI-286; SPA-110) is an analogue of Hemiasterlin; potent tubulin inhibitor; ADCs cytotoxin. -
cytotoxic tubulin modifier
Auristatin F is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAF analog and cytotoxin in Antibody-drug conjugates. Auristatin F inhibits cell division by blocking the polymerisation of tubulin. -
cytotoxic tubulin modifier
Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates. Auristatin E inhibits cell division by blocking the polymerisation of tubulin.
